The Center for AIDS Research at the University of Colorado has as its mission to """"""""to provide scientific eadership and stimulate scientific collaboration among HIV/AIDS investigators by providing institutional infrastructure and promoting scientific communication across disciplines. In addition, the CFAR will promote opportunities for training and education in AIDS research, as well as the dissemination of knowledge to the scientific and lay communities."""""""" We are focused on providing accessible and relevant support for individual investigators based on their identified needs and on developing new programs that integrate the diverse skills of groups of collaborators. These efforts are directed and bolstered by the Administrative Core through the services and scientific expertise of the four service cores: Developmental, Cellular Immunology, Applied Virology Core, and Translational. Areas of current strength include HIV Immunology, Women and Child Health, Co-infections, and Experimental Therapeutics. Developing areas are Mucosal Immunity and Tuberculosis, particularly multi-drug resistant (MDR) TB. Continued strength in AIDS research at the geographically-pivotal University of Colorado depends increasingly on a multi-disciplinary approach that transcends traditional divisional and departmental structures. The Colorado CFAR provides such an interdisciplinary support for a broad range of HIV and HIV-related investigators. For example, understanding the immuopathogenesis of HIV-1 and its interactions with co-infections (e.g, hepatitis C virus, CMV, KSHV, S. pneumoniae or Salmonellae) to develop appropriate preventive and treatment strategies for these patients requires collaboration among epidemiologists, pharmacologists, microbiologists, virologists, molecular biologists, immunologists, and infectious disease clinicians. Most importantly, studies in AIDS preventionwhether through education and behavior modification, prophylactic therapy to prevent mother-to-child transmission, or vaccine development- are by their very nature multidisciplinary. Close collaboration among social and behavioral scientists, virologists and immunologists, pediatricians and obstetricians, experts in AIDS education and AIDS clinicians are all essential to this effort, an effort supported directly and proactively by the Cores of the Colorado Center for AIDS Research.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
3P30AI054907-05S1
Application #
7617487
Study Section
Special Emphasis Panel (ZAI1-EC-A (J1))
Program Officer
Namkung, Ann S
Project Start
2003-05-15
Project End
2010-04-30
Budget Start
2008-05-22
Budget End
2010-04-30
Support Year
5
Fiscal Year
2008
Total Cost
$794,362
Indirect Cost
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Verma, Anurag; Bradford, Yuki; Verma, Shefali S et al. (2017) Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 27:101-111
Bednasz, Cindy J; Venuto, Charles S; Ma, Qing et al. (2017) Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants. Ther Drug Monit 39:596-603
Cook, Paul F; McElwain, Catherine J; Bradley-Springer, Lucy A (2016) Brief report on ecological momentary assessment: everyday states predict HIV prevention behaviors. BMC Res Notes 9:9
Wanga, Valentine; Venuto, Charles; Morse, Gene D et al. (2015) Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 25:450-61
Haas, Michelle K; Levy, David N; Folkvord, Joy M et al. (2015) Distinct patterns of Bcl-2 expression occur in R5- and X4-tropic HIV-1-producing lymphoid tissue cells infected ex vivo. AIDS Res Hum Retroviruses 31:298-304
Vardhanabhuti, Saran; Ribaudo, Heather J; Landovitz, Raphael J et al. (2015) Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia. Open Forum Infect Dis 2:ofv085

Showing the most recent 10 out of 95 publications